New combo therapy aims to shrink Hard-to-Treat cancers
NCT ID NCT07383857
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study combines a special type of radiation (PULSAR) with immunotherapy drugs to treat metastatic cancers in the abdomen and pelvis, including liver, kidney, and bladder cancers. About 103 participants will receive the treatment to see if it is safe and helps control the disease. The goal is to improve progression-free survival.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
pulsed radiotherapy (PULSAR) and PD-1 inhibitor
What this could lead to
If successful, this combination could offer a new way to control metastatic cancers in the abdomen and pelvis, potentially extending survival.
What could go wrong
This is an early-phase study with no control group, so results are uncertain. Side effects from radiation and immunotherapy may be significant.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC UROTHELIAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fudan University Shanghai Cancer Center
RECRUITINGShanghai, Shanghai Municipality, 200032, China
Contact Phone: •••-•••-•••• Email: •••••@•••••